Wegovy and Ozempic are both prescription medications that are used to treat obesity and overweight. However, they differ in several ways.

Wegovy is a new medication that was approved by the FDA in June 2021 [1]. It contains semaglutide, which is a GLP-1 receptor agonist that works by increasing feelings of fullness and reducing appetite. It is administered as a once-weekly injection and is intended for use in conjunction with a reduced-calorie diet and increased physical activity. Wegovy is only available in a 2.4 mg dose [3].

Ozempic, on the other hand, has been available since 2017 [2]. It also contains semaglutide and works in the same way as Wegovy. However, Ozempic is available in a range of doses (0.25 mg, 0.5 mg, 1 mg) and is administered as a once-weekly injection [2].

While both medications have been shown to be effective in aiding weight loss, there are some differences in their side effects and cost. According to GoodRx, Wegovy is generally more expensive than Ozempic, with a monthly cost of around $1,400 compared to Ozempic's monthly cost of around $1,000 [2].

In terms of side effects, both medications can cause nausea, diarrhea, and constipation. However, some studies have suggested that Wegovy may be associated with a higher risk of certain side effects, such as gallbladder disease and pancreatitis, compared to Ozempic [3].

Overall, both Wegovy and Ozempic are GLP-1 receptor agonists that can be effective in aiding weight loss. However, they differ in their dosing, cost, and potential side effects. It is important to consult with a healthcare provider to determine which medication may be best for an individual's specific needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.goodrx.com/classes/glp-1-agonists/wegovy-vs-ozempic
[3] https://www.uchealth.org/today/wegovy-vs-ozempic-the-truth-about-new-weight-loss-drugs/